These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34496076)

  • 21. Pharmacodynamic effects of cangrelor on platelet P2Y12 receptor-mediated signaling in prasugrel-treated patients.
    Rollini F; Franchi F; Tello-Montoliu A; Patel R; Darlington A; Ferreiro JL; Cho JR; Muñiz-Lozano A; Desai B; Zenni MM; Guzman LA; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2014 Apr; 7(4):426-34. PubMed ID: 24630878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and pharmacodynamics of a bolus and infusion of cangrelor: a direct, parenteral P2Y12 receptor antagonist.
    Akers WS; Oh JJ; Oestreich JH; Ferraris S; Wethington M; Steinhubl SR
    J Clin Pharmacol; 2010 Jan; 50(1):27-35. PubMed ID: 19779037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial.
    Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD
    Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial.
    Greenbaum AB; Ohman EM; Gibson CM; Borzak S; Stebbins AL; Lu M; Le May MR; Stankowski JE; Emanuelsson H; Weaver WD
    Am Heart J; 2007 Oct; 154(4):702-9. PubMed ID: 17892995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of Cangrelor in Cervical and Intracranial Stenting for the Treatment of Acute Ischemic Stroke: A "Real Life" Single-Center Experience.
    Cervo A; Ferrari F; Barchetti G; Quilici L; Piano M; Boccardi E; Pero G
    AJNR Am J Neuroradiol; 2020 Nov; 41(11):2094-2099. PubMed ID: 33033047
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.
    Firstenberg MS; Dyke CM; Angiolillo DJ; Ramaiahm C; Price M; Brtko M; Welsby I; Chandna H; Holmes DR; Voeltz M; Tummala P; Hutyra M; Manoukian SV; Prats J; Todd M; Liu T; Chronos N; Dietrich M; Montalescot G; Cannon LA; Topo EJ
    Heart Surg Forum; 2013 Apr; 16(2):E60-9. PubMed ID: 23625478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Periprocedural platelet inhibition with cangrelor in P2Y
    Droppa M; Spahn P; Takhgiriev K; Müller KAL; Alboji A; Straub A; Rath D; Jeong YH; Gawaz M; Geisler T
    Int J Cardiol; 2016 Nov; 223():848-851. PubMed ID: 27580219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Safety Evaluation of Cangrelor in Patients Undergoing PCI.
    Franchi F; Rollini F; Park Y; Angiolillo DJ
    Expert Opin Drug Saf; 2016; 15(2):275-85. PubMed ID: 26680584
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacodynamic Effects When Clopidogrel is Given Before Cangrelor Discontinuation.
    Schneider DJ; Agarwal Z; Seecheran N; Gogo P
    J Interv Cardiol; 2015 Oct; 28(5):415-9. PubMed ID: 26381736
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravenous cangrelor use for neuroendovascular procedures: a two-center experience and updated systematic review.
    Desai H; Al-Salihi MM; Morsi RZ; Vayani OR; Kothari SA; Thind S; Carrión-Penagos J; Baskaran A; Tarabichi A; Bonderski VA; Siegler JE; Hahn M; Coleman ER; Brorson JR; Mendelson SJ; Mansour A; Dabus G; Hurley M; Prabhakaran S; Linfante I; Kass-Hout T
    Front Neurol; 2023; 14():1304599. PubMed ID: 38116108
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Reticulated Platelets on the Antiplatelet Effect of the Intravenous P2Y12-Receptor Inhibitor Cangrelor.
    Stratz C; Nührenberg T; Valina CM; Löffelhardt N; Mashayekhi K; Ferenc M; Trenk D; Neumann FJ; Hochholzer W
    Thromb Haemost; 2018 Feb; 118(2):362-368. PubMed ID: 29443372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transition strategies from cangrelor to oral platelet P2Y12 receptor antagonists.
    Schneider DJ
    Coron Artery Dis; 2016 Jan; 27(1):65-9. PubMed ID: 26444255
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cangrelor and Stenting in Acute Ischemic Stroke : Monocentric Case Series.
    Elhorany M; Lenck S; Degos V; Sourour NA; Frasca Polara G; Shotar E; Godier A; Drir M; Mahtout J; Premat K; Alamowitch S; Samson Y; Clarençon F
    Clin Neuroradiol; 2021 Jun; 31(2):439-448. PubMed ID: 32382875
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perioperative Bridging With Glycoprotein IIb/IIIa Inhibitors Versus Cangrelor: Balancing Efficacy and Safety.
    Van Tuyl JS; Newsome AS; Hollis IB
    Ann Pharmacother; 2019 Jul; 53(7):726-737. PubMed ID: 30646761
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Periprocedural Neuroendovascular Antiplatelet Strategies for Thrombosis Prevention in Clopidogrel-Hyporesponsive Patients.
    Barra ME; Berger K; Tesoro EP; Brophy GM
    Pharmacotherapy; 2019 Mar; 39(3):317-334. PubMed ID: 30723937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of Intravenous P2Y12-Receptor Inhibition with Cangrelor in Patients Presenting with Acute Coronary Syndrome and Cardiogenic Shock - a Case Series.
    Droppa M; Borst O; Rath D; Müller K; Gawaz M; Bhatt DL; Geisler T
    Cell Physiol Biochem; 2017; 42(4):1336-1341. PubMed ID: 28700987
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series.
    Salahuddin H; Dawod G; Zaidi SF; Shawver J; Burgess R; Jumaa MA
    Front Neurol; 2021; 12():636682. PubMed ID: 34149590
    [No Abstract]   [Full Text] [Related]  

  • 38. Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
    Vaduganathan M; Harrington RA; Stone GW; Steg PG; Gibson CM; Hamm CW; Price MJ; Prats J; Deliargyris EN; Mahaffey KW; White HD; Bhatt DL
    Circ Cardiovasc Interv; 2016 Jun; 9(6):e003612. PubMed ID: 27313282
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of intravenous cangrelor and stenting in acute ischemic stroke interventions: a new single center analysis and pooled-analysis of current studies.
    Paul AR; Entezami P; Holden D; Field N; Dalfino J; Boulos A
    Interv Neuroradiol; 2021 Dec; 27(6):837-842. PubMed ID: 33945341
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacosimulation of interruptions and its solution in intravenous administration of cangrelor.
    Masyuk M; Heramvand N; Muessig JM; Nia AM; Polzin A; Kollmann M; Kelm M; Jung C
    Clin Hemorheol Microcirc; 2018; 68(4):421-425. PubMed ID: 29036802
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.